|
Current
Medicinal Chemistry
ISSN: 0929-8673

Current Medicinal Chemistry
Volume 13, Number 10, 2006
Contents

Rational Drug Design of Selective ε
Opioid Receptor Agonist TAN-821 and Antagonist TAN-1014
Pp. 1109-1118
H. Fujii and H. Nagase
[Abstract]
Chemistry and Biology of Chromatin Remodeling Agents: State
of Art and Future Perspectives of HDAC Inhibitors
Pp.1119-1139
Manuela Rodriquez, Maurizio Aquino, Ines Bruno, Giovanni
De Martino, Maurizio Taddei and Luigi Gomez-Paloma
[Abstract]
Roles of Glycans and Glycopeptides in Immune System and
Immune-Related Diseases Pp. 1141-1147
Xiao-Lian Zhang
[Abstract]
Targeting Cytokines of the Interleukin-12 Family in Autoimmunity
Pp. 1149-1156
Bok Yun Kang and Tae Sung Kim
[Abstract]
Aminolevulinic Acid Derivatives and Liposome Delivery
as Strategies for Improving 5-Aminolevulinic Acid-Mediated
Photodynamic Therapy Pp. 1157-1168
Adriana Casas and Alcira Batlle
[Abstract]
Choline Kinase: An Important Target for Cancer
Pp. 1169-1186
S. Janardhan, P. Srivani and G. Narahari Sastry
[Abstract]
Reactive Oxygen Species-Induced Gastric Ulceration:
Protection By Melatonin Pp. 1187-1202
Debashis Bandyopadhyay and Aindrila Chattopadhyay
[Abstract]
Antidiabetic Agents from Medicinal Plants
Pp. 1203-1218
Mankil Jung, Moonsoo Park, Hyun Chul Lee, Yoon-Ho Kang,
Eun Seok Kang, and Sang Ki Kim
[Abstract]
The Mercaptopyruvate Pathway in Cysteine Catabolism:
A Physiologic Role and Related Disease of the Multifunctional
3 Mercaptopyruvate Sulfurtransferase Pp. 1219-1230
Noriyuki Nagahara and Nori Sawada
[Abstract]
Abstracts

[Back to top]
Rational Drug Design of Selective
ε Opioid
Receptor Agonist TAN-821 and Antagonist TAN-1014
H. Fujii and H. Nagase
Dβ-Endorphin
(β-EP)
is generally classified as a μ
and δ
opioid receptor agonist but is also an agonist of the ε
opioid receptor. Although several selective agonists and antagonists
for μ,
δ,
and κ
opioid receptors are known, selective ε
receptor agonists or antagonists have not been reported for
some time. Recently, we designed and synthesized the selective
ε receptor
agonist, 17-(cyclopropylmethyl)-4,5α-epoxy-3,6β-dihydroxy-6,14
endoethenomorphinan-7α-[N-methyl-N-phenethyl]carboxamide
(TAN-821), and the selective ε
receptor antagonist, 17-(cyclopropylmethyl)-4,5α-epoxy-6β,
21-epoxymethano-3-hydroxy-6,14-endoe-thenomorphinan-7α-(N-phenethyl)carboxamide
(TAN-1014). TAN-821 stimulated binding of the non-hydrolyzable
guanosine 5’-triphosphate analogue, guanosine 5’-(γ-thio)-triphosphate
(GTPγS),
to the mouse pons/medulla membrane via activation
of the ε
receptor. Moreover, TAN-821 given intracerebroventricularly
(i.c.v.) produced marked, long-lasting, and dose-dependent
antinociception in tail-flick and hot-plate tests. This antinociception
induced by i.c.v. administered TAN-821 was blocked by i.c.v.
pretreatment with the ε
opioid receptor partial agonist β-EP
(1-27), but not the μ
opioid receptor antagonist β-FNA,
the δ
opioid receptor antagonist NTI, or the κ
opioid receptor antagonist nor-BNI. On the other hand, i.c.v.
injection of TAN-1014 alone produced no antinociception, and
i.c.v. pretreatment with TAN-1014 attenuated the antinociception
induced by i.c.v β-EP.
These results suggest that TAN-821 and TAN-1014 are respectively
a selective ε
receptor agonist and antagonist and that they may be useful
tools for investigating the pharmacological properties of
the ε
opioid receptor.
[Back to top]
Chemistry and Biology of Chromatin Remodeling Agents:
State of Art and Future Perspectives of HDAC Inhibitors Manuela
Rodriquez, Maurizio Aquino, Ines Bruno, Giovanni De Martino,
Maurizio Taddei and Luigi Gomez-Paloma
Chromatin remodeling is a fundamental phenomenon
in the life of eukaryotic cells, bearing implications to numerous
physiological and pathological phenomena. This review outlines
the chemistry of natural and synthetic agents endowed with
the ability to interfere with such biological function, with
a particular emphasis on histone deacetylase (HDAC) inhibitors.
Other aspects covered in this article comprise structure activity
relationships (SAR) and modes of action at molecular level,
including the description of crystal structures of enzyme-inhibitor
complexes.
[Back to top]
Roles of Glycans and Glycopeptides in Immune
System and Immune-Related Diseases
Xiao-Lian Zhang
Almost all of the key molecules in organisms involved
in the innate and adaptive immune response (including immunoglobulins,
cytokines and cytokine receptors, complements, CD molecules,
adhesions, T-cell receptors and major histocompatibility complex
molecules) are glycoproteins. Besides, foreign antigens, such
as many viral envelope proteins, are glycoproteins too. Carbohydrates
attached to proteins or peptides are classified by the nature
of their linkages to the protein, mostly as either N-linked
(N-acetylglucosamine to asparagines) or O-linked
(N-acetylgalactosamine to serine or threonine) oligosaccharides.
The glycans have three major roles: firstly, the sugars confer
stability on the proteins to which they are attached, protecting
them from proteases and non-specific protein-protein interactions.
Secondly, glycans play key roles in signal transduction, control
of cell development and differentiation. Thirdly, specific
regions of the oligosaccharide chains provide recognition
epitopes, which influence innate and adaptive immune responses.
Glycopeptides not only provide specific oligosaccharides,
but also have specific information of amino acids sequences.
The glycans and glycopeptides not only influence the structure
and functions of immune molecules, but also influence the
immune response. In addition, changes in glycans or glycopeptides
may have a significant role in a variety of human immune-related
diseases, such as rheumatoid, autoimmune disease, Wiskott-Aldrich
syndrome, infection disease, cancer, etc. In this article,
the roles of N-, O-glycans and glycopeptides in immune
system and immune-related diseases are discussed. The potential
therapeutic significance of the information is also mentioned.
[Back to top]
Targeting Cytokines of the Interleukin-12 Family in
Autoimmunity
Bok Yun Kang and Tae Sung Kim
In the past, autoimmunity was thought to be mediated by antibodies
and immune complexes. It has now become clear that many autoimmune
diseases, especially tissue specific, are T cell-mediated,
or at least T cell-dependent. The pathogenesis of cell-mediated
autoimmune diseases, including multiple sclerosis, uveitis,
diabetes, arthritis, and others, is now thought to be, in
a large measure, driven by interferon-γ-producing,
antigen-specific T cells, which are polarized toward the T
helper type 1 (Th1) phenotype. Interleukin (IL)-12 and the
more recently discovered IL-23 and IL-27 constitute a unique
family of structurally-related, heterodimeric cytokines, which
regulate cell-mediated immune responses and Th1-type inflammatory
reactions. Thus, these cytokines may have a central role in
the development and progression of cell-mediated autoimmune
diseases. Therefore, pharmacologically targeting cytokines
of the IL-12 family would be useful in the modulation of several
autoimmune diseases. This review summarizes the recent findings
concerning IL-12 family cytokine-mediated autoreactive inflammatory
responses, and also describes some possible therapeutic interventions,
including medicinal compounds at mitigating autoimmune inflammation.
[Back to top]
Aminolevulinic Acid Derivatives and Liposome Delivery
as Strategies for Improving 5-Aminolevulinic Acid-Mediated
Photodynamic Therapy
Adriana Casas and Alcira Batlle
Photodynamic Therapy employing 5-aminolevulinic acid
(ALA) as a precursor of the photosensitizer Protoporphyrin
IX has become a promising approach to treat superficial cancers.
However, the hydrophilic nature of the ALA molecule somewhat
limits the penetration through the skin as well as all cell
membranes. Different attempts are currently under investigation
to enhance ALA penetration, such as the development of new
synthetic and more lipophilic molecules derived from ALA and
the incorporation of ALA into lipophilic vehicles such as
liposomes. Among the new synthesized molecules, we can find
ALA esters, ALA aminoacid derivatives and ALA dendrimers.
In general, there is consensus that the promising results
obtained in vitro with ALA esters cannot be reproduced
in vivo. However, ALA methyl ester (1) has been widely
used for treatment of skin malignancies and ALA hexyl ester
(15) proved to be more powerful than ALA in bladder imaging.
ALA aminoacid derivatives have been designed to use specific
cellular aminopeptidases to targeting tumors, and it was shown
that they can be metabolized to ALA with some specificity.
[Back to top]
Choline Kinase: An Important Target for Cancer
S. Janardhan, P. Srivani and G. Narahari Sastry
Choline kinase (ChoK) is a cytosolic enzyme present in various
tissues, whcih catalyzes the phosphorylation of choline to
form phosphorylcholine (PCho) in the presence of ATP and magnesium.
ChoK is important for the generation of two major membrane
phospholipids, phosphatidylcholine (PC) and sphingomyelin
(SM) and subsequently for the cell division. ChoK plays a
vital role in cell signaling pathways and regulation of cell
growth along with PCho involved in malignant transformation
through ras oncogenes in different cancers such as
breast, lung, colon, prostate, neuroblastoma, hepatic lymphomas,
meningiomas and diverse murine tumours. The Ras effectors
serine/threonine kinase (Raf-1), the Ral-GDP dissociation
stimulator (Ral-GDS) and the phosphatidylinositol 3-kinase
(PI3K) are involved in the activation of ChoK during tumorigenesis.
ChoK gene induction seems to be associated with certain cell
stress or cell defense. Nowadays, RNAi appear to be one of
the most promising routes in the cancer therapy. The anticancer
potential of both stable expression of siRNAs and their high
sequence specificity by RNAi mediated suppression of oncogenic
ras in human pancreatic carcinoma, human melanomas
and ovarian cancer has been observed. It has an important
role in sequence specific post-transcriptional gene silencing
mechanism. Presently, the crystal structure of Caenorhabditis
elegans choline kinase A-2 (ChoKA-2) is available, which
may be useful for comparative modeling of human ChoK and further
modeling studies. The present review aims at the general overview
of importance, expression, structure, progress in molecular
modeling, active site analysis and inhibitors of ChoK. It
also highlights the recent role of ChoK in various types of
Ras-dependent and Ras-independent carcinogenesis.
[Back to top]
Reactive Oxygen Species-Induced Gastric Ulceration:
Protection By Melatonin
Debashis Bandyopadhyay and Aindrila Chattopadhyay
Gastric hyperacidity and ulceration of the stomach mucosa
due to various factors are serious health problems of global
concern. Although the mechanism of acid secretion from the
parietal cells is now well understood, the processes involved
in gastric ulceration are still not clear. Among the various
causes of gastric ulceration, lesions caused by stress, alcohol
consumption, Helicobacter pylori and due to use of
non-steroidal anti-inflammatory drugs have been shown to be
mediated largely through the generation of reactive oxygen
species, especially the hydroxyl radical. A number of excellent
drugs, developed over the decades, have proven useful in controlling
hyperacidity and ulceration although their long-term use is
reported to be associated with various side effects. Hence
the investigations continue with an objective to find a compound
possessing anti-secretory, anti-ulcer and antioxidant properties
which will serve as a therapeutic agent to reduce gastric
hyperacidity and ulcers. This article describes the role of
reactive oxygen species in gastric ulceration, briefly presents
a note on the currently available drugs controlling them,
and focuses on the role of melatonin, a pineal secretory product,
in protecting against gastric lesions. In experimental studies,
melatonin has been shown to be effective in reducing mucosal
breakdown and ulcer formation in a wide variety of situations.
Additionally, the low toxicity of melatonin supports further
investigation of this molecule as a promising gastro-protective
agent. Finally, we include a commentary on how melatonin research
with respect to gastric pathophysiology can move forward with
a view to eventually using this indole as a therapeutic agent
alone or in combination with the existing drugs to control
gastric ulceration in humans in order to increase their efficacy
and / or to reduce their side effects.
[Back to top]
Antidiabetic Agents from Medicinal Plants
Mankil Jung, Moonsoo Park, Hyun Chul Lee, Yoon-Ho Kang,
Eun Seok Kang, and Sang Ki Kim
Currently available therapeutic options for non–insulin-dependent
diabetes mellitus, such as dietary modification, oral hypoglycemics,
and insulin, have limitations of their own. Many natural products
and herbal medicines have been recommended for the treatment
of diabetes. The present paper reviews medicinal plants that
have shown experimental or clinical antidiabetic activity
and that have been used in traditional systems of medicine;
the review also covers natural products (active natural components
and crude extracts) isolated from the medicinal plants and
reported during 2001 to 2005. Many kinds of natural products,
such as terpenoids, alkaloids, flavonoids, phenolics, and
some others, have shown antidiabetic potential. Particularly,
schulzeines A, B, and C, radicamines A and B, 2,5-imino-1,2,5-trideoxy-L-glucitol,
β-homofuconojirimycin,
myrciacitrin IV, dehydrotrametenolic acid, corosolic acid
(Glucosol™), 4-(α-rhamnopyranosyl)ellagic
acid, and 1,2,3,4,6-pentagalloylglucose have shown significant
antidiabetic activities. Among active medicinal herbs, Momordica
charantia L. (Cucurbitaceae), Pterocarpus marsupium
Roxb. (Leguminoceae), and Trigonella foenum graecum
L. (Leguminosae) have been reported as beneficial for treatment
of type 2 diabetes.
[Back to top]
The Mercaptopyruvate Pathway in Cysteine Catabolism:
A Physiologic Role and Related Disease of the Multifunctional
3 Mercaptopyruvate Sulfurtransferase
Noriyuki Nagahara and Nori Sawada
The conversion of cysteine to 3-sulfino-alanine is a
major pathway in cysteine catabolism. Cysteine dioxygenase
catalyzes the reaction and dietary intake of the essential
amino acid methionine and the semi-essential amino acid cysteine
increases the level of this enzyme by suppressing enzyme degradation
via polyubiquitination.
The production of cellular antioxidants such as glutathione,
thioredoxin, and their families is important in cysteine metabolism,
and these cellular antioxidants have critical roles in the
maintenance of the cellular redox status. The mercaptopyruvate
pathway, in which cysteine or aspartate transaminase catalyzes
the transamination from cysteine to 3-mercaptopyruvate and
then 3-mercaptopyruvate sulfurtransferase catalyzes the transsulfuration
from 3-mercaptopyruvate to pyruvate, also contributes to maintein
the cellular redox. 3-Mercaptopyruvate sulfurtransferase serves
as an antioxidant protein: when the enzyme is exposed to stoichiometric
amounts of the oxidant hydrogen peroxide, it is inhibited
via the formation of low redox sulfenate at the catalytic
site cysteine. On the other hand, activity is restored by
the reductant dithiothreitol or reduced thioredoxin.
3-Mercaptopyruvate sulfurtransferase also detoxifies cyanide
via transsulfuration from a stable persulfide at
the catalytic site cysteine, a reaction intermediate, suggesting
that cyanide detoxification is not necessarily an enzymatic
reaction. Furthermore, a congenital defect of the enzyme causes
mercaptolactate-cysteine disulfiduria associated with or without
mental retardation, although the pathogenesis remains unclear.
These facts suggest that 3-mercaptopyruvate sulfurtransferase
has physiologic roles as an antioxidant and a cyanide antidote;
is essential for neural function, and participates in cysteine
degradation.
|